Načítá se...
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR
Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally a...
Uloženo v:
Vydáno v: | Oncotarget |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Impact Journals LLC
2015
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868683/ https://ncbi.nlm.nih.gov/pubmed/26496029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6169 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|